Expert Opinion On Therapeutic Targets

杂志介绍

Expert Opinion On Therapeutic Targets杂志介绍

《Expert Opinion On Therapeutic Targets》是一本以English为主的未开放获取国际优秀期刊，中文名称治疗靶点专家意见，本刊主要出版、报道医学-PHARMACOLOGY & PHARMACY领域的研究动态以及在该领域取得的各方面的经验和科研成果，介绍该领域有关本专业的最新进展，探讨行业发展的思路和方法，以促进学术信息交流，提高行业发展。该刊已被国际权威数据库SCIE收录，为该领域相关学科的发展起到了良好的推动作用，也得到了本专业人员的广泛认可。该刊最新影响因子为4.6，最新CiteScore 指数为8.9。

本刊近期中国学者发表的论文主要有：

• Targeting endoplasmic reticulum stress-the responder to lipotoxicity and modulator of non-alcoholic fatty liver diseases

  Author: Luo, Yu; Jiao, Qiangqiang; Chen, Yuping

• The participation of non-canonical autophagic proteins in the autophagy process and their potential as therapeutic targets

  Author: Yin, Yiming; Zhou, Yourong; Yang, Xiaochun; Xu, Zhifei; Yang, Bo; Luo, Peihua; Yan, Hao; He, Qiaojun

• Novel therapeutic perspectives for crescentic glomerulonephritis through targeting parietal epithelial cell activation and proliferation

  Author: Huang, Yanjie; Zhao, Xueru; Zhang, Qiushuang; Yang, Xiaoqing; Hou, Gailing; Peng, Chaoqun; Jia, Mengzhen; Zhou, Li; Yamamoto, Tatsuo; Zheng, Jian

• Recent advances of Phosphodiesterase 4B in cancer

  Author: Miao, Yu; Peng, Li; Chen, Zhaolin; Hu, Ying; Tao, Liangsong; Yao, Yan; Wu, Yincui; Yang, Dashuai; Xu, Tao

英文介绍

Expert Opinion On Therapeutic Targets杂志英文介绍

The journal evaluates molecules, signalling pathways, receptors and other therapeutic targets and their potential as candidates for drug development. Articles in this journal focus on the molecular level and early preclinical studies. Articles should not include clinical information including specific drugs and clinical trials.

The Editors welcome:

Reviews covering novel disease targets at the molecular level and information on early preclinical studies and their implications for future drug development.

Articles should not include clinical information including specific drugs and clinical trials.

Original research papers reporting results of target selection and validation studies and basic mechanism of action studies for investigative and marketed drugs.

The audience consists of scientists, managers and decision makers in the pharmaceutical industry, academic researchers working in the field of molecular medicine and others closely involved in R&D.